BR112022010627A2 - Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados - Google Patents
Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionadosInfo
- Publication number
- BR112022010627A2 BR112022010627A2 BR112022010627A BR112022010627A BR112022010627A2 BR 112022010627 A2 BR112022010627 A2 BR 112022010627A2 BR 112022010627 A BR112022010627 A BR 112022010627A BR 112022010627 A BR112022010627 A BR 112022010627A BR 112022010627 A2 BR112022010627 A2 BR 112022010627A2
- Authority
- BR
- Brazil
- Prior art keywords
- idiotypic antibodies
- bcma
- methods
- binding domains
- related compositions
- Prior art date
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title abstract 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title abstract 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS ANTI-IDIOTÍPICOS PARA DOMÍNIOS DE LIGAÇÃO ALVEJADOS POR BCMA E COMPOSIÇÕES E MÉTODOS RELACIONADOS. A presente invenção refere-se a anticorpos anti-idiotípicos que especificamente reconhecem porções de anticorpo anti-BCMA, em particular, porções de anticorpo anti-BCMA presentes em receptores recombinantes, incluindo receptores de antígeno quimérico (CARs). A invenção também se refere a usos de anticorpos anti-idiotípicos para especificamente identificar e/ou selecionar células que expressam tais receptores recombinantes, tais como, células T CAR anti-BCMA. A invenção também se refere a usos de anticorpos anti-idiotípicos para especificamente ativar tais células.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962945065P | 2019-12-06 | 2019-12-06 | |
US202063061763P | 2020-08-05 | 2020-08-05 | |
US202063109839P | 2020-11-04 | 2020-11-04 | |
PCT/US2020/063492 WO2021113776A1 (en) | 2019-12-06 | 2020-12-04 | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010627A2 true BR112022010627A2 (pt) | 2022-08-16 |
Family
ID=74046191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010627A BR112022010627A2 (pt) | 2019-12-06 | 2020-12-04 | Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230028050A1 (pt) |
EP (1) | EP4069741A1 (pt) |
JP (1) | JP2023504740A (pt) |
KR (1) | KR20220122653A (pt) |
CN (1) | CN115916817A (pt) |
AU (1) | AU2020395319A1 (pt) |
BR (1) | BR112022010627A2 (pt) |
CA (1) | CA3163897A1 (pt) |
IL (1) | IL293430A (pt) |
MX (1) | MX2022006709A (pt) |
WO (1) | WO2021113776A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2023104138A1 (zh) * | 2021-12-09 | 2023-06-15 | 江苏先声药业有限公司 | Bcma抗体及其应用 |
CN117343179A (zh) * | 2022-07-04 | 2024-01-05 | 苏州星湾生物科技有限公司 | 检测抗bcma car表达水平的单克隆抗体及其应用 |
WO2024064600A2 (en) * | 2022-09-19 | 2024-03-28 | Allogene Therapeutics Inc. | B-cell maturation antigen (bcma) anti-idiotypic antibodies |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5266191A (en) | 1992-08-27 | 1993-11-30 | Newberry Tanks & Equipment, Inc. | Immiscible liquids separator apparatus and method |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
WO1997015399A1 (en) | 1996-04-24 | 1997-05-01 | Claude Fell | Cell separation system for biological fluids like blood |
US5699751A (en) | 1996-10-02 | 1997-12-23 | Embrex, Inc. | Method and apparatus for in ovo injection |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
JP4514338B2 (ja) | 1998-12-24 | 2010-07-28 | ビオセフ エス・アー | 造血幹細胞の濃縮に特化した血液分離装置 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
AU2001294198C1 (en) | 2000-10-06 | 2019-04-04 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
DE60122765D1 (de) | 2000-11-07 | 2006-10-12 | Hope City | Cd19-spezifische umgezielte immunzellen |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
NZ603111A (en) | 2001-08-03 | 2014-05-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
DE60232265D1 (de) | 2001-10-25 | 2009-06-18 | Genentech Inc | Glycoprotein-zusammensetzungen |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変 |
ES2393555T3 (es) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide. |
CN102373214B (zh) | 2003-11-05 | 2014-07-09 | 罗氏格黎卡特股份公司 | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 |
JP5020636B2 (ja) | 2003-11-06 | 2012-09-05 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
DE602006014399D1 (de) | 2005-03-23 | 2010-07-01 | Biosafe Sa | Integriertes system zum sammeln, bearbeiten und transplantieren von zell-subsets, einschliesslich adulter stammzellen, für die regenerative medizin |
CA2665826A1 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc | Molecules with reduced half-lives, compositions and uses thereof |
EP3357338A1 (en) | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
HUE034888T2 (hu) | 2007-12-07 | 2018-03-28 | Miltenyi Biotec Gmbh | Sejtfeldolgozási rendszerek és eljárások |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
HRP20211788T1 (hr) | 2008-08-26 | 2022-02-18 | City Of Hope | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica |
HUE044461T2 (hu) | 2009-11-03 | 2019-10-28 | Hope City | Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz |
US20130102087A1 (en) | 2010-04-15 | 2013-04-25 | Harvey Lee Kasdan | Device, system and method for rapid determination of a medical condition |
EP2611834B1 (en) * | 2010-09-01 | 2018-03-07 | Biogen MA Inc. | Rapid generation of anti-idiotypic antibodies |
AU2011338200B2 (en) | 2010-12-09 | 2017-02-23 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified T cells to treat cancer |
CN106074601A (zh) | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
KR102276888B1 (ko) | 2012-05-03 | 2021-07-14 | 프레드 헛친슨 켄서 리서치 센터 | 증강된 친화성 t 세포 수용체 및 이의 제조 방법 |
RU2019126655A (ru) | 2012-08-20 | 2019-11-12 | Фред Хатчинсон Кансэр Рисёч Сентер | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
US20140170678A1 (en) | 2012-12-17 | 2014-06-19 | Leukodx Ltd. | Kits, compositions and methods for detecting a biological condition |
EP2932268A4 (en) | 2012-12-17 | 2016-10-19 | Leukodx Ltd | SYSTEMS AND METHOD FOR RECOGNIZING A BIOLOGICAL CONDITION |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
IL280738B (en) | 2014-04-16 | 2022-07-01 | Juno Therapeutics Gmbh | Methods, kits and device for increasing cell populations |
MX2017005823A (es) | 2014-11-05 | 2017-08-02 | Juno Therapeutics Inc | Metodos para transduccion y procesamiento celular. |
PT3227432T (pt) | 2014-12-05 | 2023-12-06 | Eureka Therapeutics Inc | Recetores de antigénios quiméricos que visam o antigénio de maturação das células b e sua utilização |
WO2019089798A1 (en) * | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
MA50860A (fr) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants |
JP7233425B2 (ja) * | 2017-11-06 | 2023-03-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ |
EP3752531A1 (en) * | 2018-02-14 | 2020-12-23 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
-
2020
- 2020-12-04 CN CN202080095372.0A patent/CN115916817A/zh active Pending
- 2020-12-04 KR KR1020227022869A patent/KR20220122653A/ko unknown
- 2020-12-04 EP EP20829468.6A patent/EP4069741A1/en active Pending
- 2020-12-04 IL IL293430A patent/IL293430A/en unknown
- 2020-12-04 WO PCT/US2020/063492 patent/WO2021113776A1/en unknown
- 2020-12-04 MX MX2022006709A patent/MX2022006709A/es unknown
- 2020-12-04 AU AU2020395319A patent/AU2020395319A1/en active Pending
- 2020-12-04 CA CA3163897A patent/CA3163897A1/en active Pending
- 2020-12-04 US US17/781,693 patent/US20230028050A1/en active Pending
- 2020-12-04 JP JP2022534169A patent/JP2023504740A/ja active Pending
- 2020-12-04 BR BR112022010627A patent/BR112022010627A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2020395319A1 (en) | 2022-07-14 |
CN115916817A (zh) | 2023-04-04 |
CA3163897A1 (en) | 2021-06-10 |
IL293430A (en) | 2022-07-01 |
US20230028050A1 (en) | 2023-01-26 |
WO2021113776A1 (en) | 2021-06-10 |
KR20220122653A (ko) | 2022-09-02 |
EP4069741A1 (en) | 2022-10-12 |
MX2022006709A (es) | 2022-09-12 |
JP2023504740A (ja) | 2023-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022010627A2 (pt) | Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados | |
MX2019001184A (es) | Anticuerpos anti-idiotípicos y métodos relacionados. | |
CO2018001405A2 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple | |
CO2017006808A2 (es) | Receptores de antígenos quiméricos de bcma | |
CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
UY35063A (es) | Composiciones y métodos que se dirigen a células estromales para el tratamiento del cáncer | |
BR112017003505A2 (pt) | anticorpos e receptores de antígeno quiméricos específicos para cd19 | |
CO2019013614A2 (es) | Dominio de unión a antígeno | |
ECSP17054182A (es) | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 | |
BR112016022369A2 (pt) | receptores quiméricos de antígeno cd33-específicos para imunoterapia contra o câncer | |
BR112022008522A2 (pt) | Usos de receptores de antígeno quimérico anti-bcma | |
MX2016006303A (es) | Celula. | |
EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
BR112017019914A2 (pt) | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b | |
BR112017014547A2 (pt) | sistemas de receptor de antígeno quimérico dirigidos por mab para classificação/depleção de células imunes engenheiradas | |
EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
BR112016022841A8 (pt) | Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo | |
AR077594A1 (es) | Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t) | |
CL2016001256A1 (es) | Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14). | |
NZ735778A (en) | Kappa myeloma antigen chimeric antigen receptors and uses thereof | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |